Have FDA’s Generic Approvals Helped With Competition? Researchers Say Too Early to Tell

Amid increasing abbreviated new drug application (ANDA) approvals, efforts by the US Food and Drug Administration (FDA) to promote generic drug development in areas where competition is lacking and for shortage-prone drugs have yet to make a noticeable impact, according a paper published in JAMA Network Open on Friday.